Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial
Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial. // The Lancet Diabetes & Endocrinology. – URL: https://www.sciencedirect.com/science/article/pii/S2213858726002329?dgcid=rss_sd_all
Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial. The Lancet Diabetes & Endocrinology. https://www.sciencedirect.com/science/article/pii/S2213858726002329?dgcid=rss_sd_all
“Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial.” The Lancet Diabetes & Endocrinology.
@article{article68476,
title = {Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial},
journal = {The Lancet Diabetes \& Endocrinology},
url = {https://www.sciencedirect.com/science/article/pii/S2213858726002329?dgcid=rss_sd_all}
}
Abstract Background Macrophage polarisation plays a crucial role in sepsis‐associated inflammatory responses; however, the underlying molecular regulatory mechanisms remain to be further explored. Aim This study aimed to explore the...